Clinical Trials Logo

Clinical Trial Summary

To demonstrate the comparative effectiveness of 12 months of Lucentis (ranibizumab) in patients with well controlled compared to those with poorly controlled diabetes using an PRN treatment schedule.


Clinical Trial Description

To demonstrate the comparative effectiveness of Lucentis (ranibizumab) in patients with well controlled compared to those with poorly controlled diabetes.

The primary endpoint for the study will be the mean change in best-corrected visual acuity (BCVA) from baseline to Month 12.

Two groups of patients, based on HbA1c levels will be entered into the trial -

1. patients with a recent HbA1c level < 7.5 % (the 'well controlled' subgroup) and

2. patients with a recent HbA1c level ≥ 10.0% (the 'poorly controlled' subgroup).

Ranibizumab treatment will be administered over the 12-month period, initial 3 monthly injections, followed by 'as needed' protocol using the following principles:

Monthly ranibizumab injections would be suspended when:

- No further BCVA improvement from treatment at the last 2 consecutive follow up visits OR

- BCVA letter score >84 (6/6) at the last 2 consecutive follow up visits

Monthly ranibizumab injections would be reinitiated when:

• Decrease in BCVA due to DME progression in the opinion of the investigator Laser treatment could also be administered from 3 months after study initiation, according to the investigators decision, in accordance with ETDRS guidelines, and at intervals of at least 3 months from the last treatment.

Visit schedule: Screening visit then monthly visits for 12 visits (total of 13 visits) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03495765
Study type Interventional
Source Marsden Eye Specialists
Contact
Status Completed
Phase Phase 3
Start date March 2011
Completion date January 1, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02554747 - Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Phase 4
Recruiting NCT02309476 - Sub-threshold Photocoagulation of Diabetic Macular Oedema N/A
Active, not recruiting NCT02207712 - Noctura400 Treatment for Diabetic Retinopathy (CANDLE) N/A
Active, not recruiting NCT02457884 - Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema N/A
Completed NCT00148330 - Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study Phase 2/Phase 3
Completed NCT00167518 - Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO) Phase 2/Phase 3
Completed NCT01787669 - Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema Phase 2
Not yet recruiting NCT02181400 - Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema N/A
Completed NCT01175070 - Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Phase 4
Terminated NCT00427986 - Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema N/A
Completed NCT00333671 - Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema) N/A
Active, not recruiting NCT02731911 - Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study N/A
Completed NCT00148265 - A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Phase 2/Phase 3